Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study

[1]  T. Yoshizaki,et al.  Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome , 2016, Heart and Vessels.

[2]  I. Tatsuno.  Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia , 2014, Expert review of cardiovascular therapy.

[3]  J. DiNicolantonio,et al.  Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. , 2014, Thrombosis research.

[4]  I. Komuro,et al.  Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. , 2014, The American journal of cardiology.

[5]  T. Ninomiya,et al.  Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. , 2013, Atherosclerosis.

[6]  M. Davidson.  Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid , 2013, Current opinion in lipidology.

[7]  M. Roncaglioni,et al.  n-3 fatty acids in patients with multiple cardiovascular risk factors. , 2013, The New England journal of medicine.

[8]  A. Sato,et al.  Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. , 2013, The American journal of cardiology.

[9]  J. Geleijnse,et al.  Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? , 2012, European heart journal.

[10]  M. Nobuyoshi,et al.  Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[11]  D. Mozaffarian,et al.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. , 2011, Journal of the American College of Cardiology.

[12]  T. A. Jacobson,et al.  Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis , 2011, Current atherosclerosis reports.

[13]  L. Kuller,et al.  Differential Association of Docosahexaenoic and Eicosapentaenoic Acids With Carotid Intima-Media Thickness , 2011, Stroke.

[14]  Y. Matsuzawa,et al.  Relationships between plasma fatty acid composition and coronary artery disease. , 2011, Journal of atherosclerosis and thrombosis.

[15]  G. Einvik,et al.  A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[16]  A. Sala-Vila,et al.  Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia. , 2010, The American journal of clinical nutrition.

[17]  B. Scirica,et al.  Acute coronary syndrome: emerging tools for diagnosis and risk assessment. , 2010, Journal of the American College of Cardiology.

[18]  K. Fukao,et al.  Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. , 2010, Journal of atherosclerosis and thrombosis.

[19]  H. Shimokawa,et al.  Potential usefulness of fish oil in the primary prevention of acute coronary syndrome. , 2010, European heart journal.

[20]  Y. Jang,et al.  Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute myocardial infarction--data from Infarction Prognosis Study (IPS) Registry. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[21]  Y. Matsuzawa,et al.  Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). , 2009, Atherosclerosis.

[22]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  Y. Matsuzawa,et al.  Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[24]  Y. Matsuzawa,et al.  Erratum to “Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)” [Atherosclerosis 200 (2008) 135–140] , 2009 .

[25]  Masayuki Yoshida,et al.  Apolipoprotein CIII links dyslipidemia with atherosclerosis. , 2009, Journal of atherosclerosis and thrombosis.

[26]  Y. Matsuzawa,et al.  Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). , 2008, Atherosclerosis.

[27]  Kortaro Tanaka,et al.  Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients: Subanalysis of the JELIS Trial , 2008, Stroke.

[28]  H. Roche,et al.  Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. , 2007, The Journal of nutritional biochemistry.

[29]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[30]  A. Lichtenstein,et al.  Higher plasma docosahexaenoic acid is associated with reduced progression of coronary atherosclerosis in women with CAD Published, JLR Papers in Press, September 18, 2006. , 2006, Journal of Lipid Research.

[31]  Harri Rissanen,et al.  Intake of fish and long-chain n-3 fatty acids and the risk of coronary heart mortality in men and women. , 2006, The British journal of nutrition.

[32]  R. Huupponen,et al.  Effects of Diet and Simvastatin on Fatty Acid Composition in Hypercholesterolemic Men: A Randomized Controlled Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[33]  R. Buckley,et al.  Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects , 2004, British Journal of Nutrition.

[34]  K. Witte,et al.  Fish oils – adjuvant therapy in chronic heart failure? , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[35]  J. Manson,et al.  Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. , 2004, The Journal of nutrition.

[36]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[37]  G. Watts,et al.  Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. , 2003, Atherosclerosis.

[38]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[39]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[40]  G. Watts,et al.  Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men , 2000, Circulation.

[41]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[42]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[43]  T. Mori,et al.  Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. , 1999, Hypertension.

[44]  S Greenland,et al.  Basic problems in interaction assessment. , 1993, Environmental health perspectives.

[45]  Y. Goto,et al.  Effects of eicosapentaenoic acid on plasma lipoprotein subfractions and activities of lecithin:cholesterol acyltransferase and lipid transfer protein. , 1991, Atherosclerosis.

[46]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[47]  S Greenland,et al.  Modeling and variable selection in epidemiologic analysis. , 1989, American journal of public health.

[48]  H. Uchino,et al.  DEPARTMENT OF INTERNAL MEDICINE , 1966 .